Modulation of the Renin-Angiotensin-Aldosterone System in Heart Failure

被引：0
作者：
J. George
A. D. Struthers
C. C. Lang
机构：
[1] University of Dundee,Division of Cardiovascular & Diabetes Medicine, Medical Research Institute
[2] Mailbox 2,Division of Cardiovascular & Diabetes Medicine
[3] Ninewells Hospital and Medical School,undefined
来源：
Current Atherosclerosis Reports | 2014年 / 16卷
关键词：
Novel therapy; Treatment; Drugs; Renin-angiotensin-aldosterone blockers; Chronic heart failure; Reduced/preserved ejection fraction;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The renin-angiotensin-aldosterone system (RAAS) is well-established and continues to be pursued as a therapeutic target in the treatment of heart failure, predominantly due to the success of agents that block RAAS in clinical trials of systolic heart failure. The optimal treatment of heart failure patients with preserved ejection fraction (HFpEF), however, remains unclear. Early trials of direct renin inhibitors have suggested that these agents may play a role in HFpEF, but recent clinical trial results have not been encouraging. Preliminary trials of angiotensin-receptor/neprilysin inhibitors look promising. Whether results with these or other drugs will alter current recommendations remains to be seen. In this review, we assess the current understanding of the role of RAAS modulation in heart failure.
引用
收藏
相关论文
共 209 条
  • [1] McMurray JJ(2012)ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC Eur J Heart Fail 14 803-869
  • [2] Adamopoulos S(2010)Clinical practice. Systolic heart failure N Engl J Med 362 228-238
  • [3] Anker SD(2010)Trends in length of stay and short-term outcomes among medicare patients hospitalized for heart failure, 1993-2006 Jama 303 2141-2147
  • [4] McMurray JJ(2012)Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes Circulation 126 65-75
  • [5] Bueno H(2011)Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment Eur Heart J 32 670-679
  • [6] Ross JS(1997)The effect of digoxin on mortality and morbidity in patients with heart failure N Engl J Med 336 525-533
  • [7] Wang Y(1991)Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators N Engl J Med 325 293-302
  • [8] Steinberg BA(1987)Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north scandinavian enalapril survival study (CONSENSUS) N Engl J Med 316 1429-1435
  • [9] Zhao X(1992)Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators N Engl J Med 327 669-677
  • [10] Heidenreich PA(2012)Reverse remodeling in heart failure–mechanisms and therapeutic opportunities Nat Rev Cardiol 9 147-157
12345678910